These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8750979)

  • 21. Tardive dyskinesia: are first signs reversible?
    Quitkin F; Rifkin A; Gochfeld L; Klein DF
    Am J Psychiatry; 1977 Jan; 134(1):84-7. PubMed ID: 12666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Two cases of tardive Tourette syndrome].
    Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(5):459-65. PubMed ID: 16869393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Medicolegal aspects of tardive dyskinesia in the United States].
    Wolf MA; Grunberg F; Garneau Y
    Encephale; 1988; 14(3):133-8. PubMed ID: 2900134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical and typical neuroleptics and tardive dyskinesia.
    Borison RL; Shah C; White TH; Diamond BI
    Psychopharmacol Bull; 1987; 23(1):218-20. PubMed ID: 3602323
    [No Abstract]   [Full Text] [Related]  

  • 25. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tardive dyskinesia following after small doses of neuroleptics].
    Bjørndal F; Rasmussen PT
    Ugeskr Laeger; 1982 Mar; 144(12):871-2. PubMed ID: 6125047
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tardive dyskinesia following after neuroleptics in small doses].
    Rasmussen PT; Bjørndal F
    Ugeskr Laeger; 1982 Mar; 144(12):894-5. PubMed ID: 6125048
    [No Abstract]   [Full Text] [Related]  

  • 28. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiparkinsonics, neuroleptics, and tardive dyskinesia.
    Mallya A; Jose C; Baig M; Williams R; Cho D; Mehta D; Volavka J
    Biol Psychiatry; 1979 Aug; 14(4):645-9. PubMed ID: 39640
    [No Abstract]   [Full Text] [Related]  

  • 31. Propranolol for tardive dyskinesia and extrapyramidal side effects (pseudoparkinsonism) from neuroleptics.
    Kulik FA; Wilbur R
    Psychopharmacol Bull; 1980 Jul; 16(3):18-9. PubMed ID: 6105690
    [No Abstract]   [Full Text] [Related]  

  • 32. Tardive dyskinesia and second-generation antipsychotics.
    Ross DE
    Am J Psychiatry; 2005 Feb; 162(2):405; author reply 405-6. PubMed ID: 15677620
    [No Abstract]   [Full Text] [Related]  

  • 33. Depression as a risk factor in tardive dyskinesia.
    Rush M; Diamond F; Alpert M
    Biol Psychiatry; 1982 Mar; 17(3):387-92. PubMed ID: 6123350
    [No Abstract]   [Full Text] [Related]  

  • 34. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Severe tardive dyskinesia during treatment with risperidone and fluoxetine].
    Dubbelman YD; Thung FH; Heeringa M
    Ned Tijdschr Geneeskd; 1998 Jun; 142(26):1508-11. PubMed ID: 9752071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
    Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Late extrapyramidal hyperkinesis and neuroleptic withdrawal dyskinesia. Practical problems].
    Hoffmann C; Faust V
    Fortschr Med; 1983 Mar; 101(11):470-6. PubMed ID: 6133824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2008 Aug; 590(1-3):241-5. PubMed ID: 18590723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():15-20. PubMed ID: 10739326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of the incidence of tardive dyskinesias in 3 groups of patients treated with different neuroleptics].
    Barcia D; Pozo P; Ruiz ME; Forcadell F; Morcillo L; Soria JM; Carrasco E
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1987; 15(1):25-8. PubMed ID: 3577874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.